Datasets:

ClarusC64
/

pharma-market-access-value-manifold-construction-v0.1

id stringclasses 6 values	therapy_area stringclasses 6 values	compound stringclasses 6 values	indication stringclasses 6 values	comparator_context stringclasses 6 values	efficacy_summary stringclasses 6 values	safety_summary stringclasses 4 values	real_world_evidence_notes stringclasses 6 values	cost_profile_summary stringclasses 4 values	payer_context_notes stringclasses 6 values	clinical_benefit_axis float64 0.58 0.9	comparator_advantage_score float64 0.4 0.85	cost_effectiveness_position stringclasses 4 values	evidence_strength_index float64 0.55 0.74	narrative_alignment_score float64 0.59 0.8	payer_acceptance_baseline float64 0.5 0.7	confidence_score float64 0.68 0.78	notes stringclasses 6 values	constraints stringclasses 1 value	gold_checklist stringclasses 1 value
VMC-001	oncology	drug-A	metastatic solid tumor	SOC chemo	OS +4m	manageable AE	registry supports benefit	high cost	US commercial	0.78	0.66	borderline	0.74	0.7	0.62	0.76	strong but costly	Under 240 words	benefit+comp+cost+evidence+narrative+accept+confidence
VMC-002	autoimmune	drug-B	RA	TNF inhibitors	ACR improvement	good safety	RWE supportive	moderate cost	EU payer strict	0.72	0.6	acceptable	0.7	0.68	0.58	0.72	competitive	Under 240 words	benefit+comp+cost+evidence+narrative+accept+confidence
VMC-003	cardio	drug-C	HFpEF	ACEi baseline	small benefit	clean safety	limited RWE	low cost	broad access	0.58	0.4	strong	0.55	0.62	0.7	0.68	weak efficacy	Under 240 words	benefit+comp+cost+evidence+narrative+accept+confidence
VMC-004	rare disease	drug-D	enzyme deficiency	none	large effect	moderate AE	small RWE	very high cost	HTA strict	0.9	0.85	weak	0.68	0.8	0.5	0.78	orphan case	Under 240 words	benefit+comp+cost+evidence+narrative+accept+confidence
VMC-005	metabolic	drug-E	T2D	GLP-1	HbA1c modest	good safety	RWE neutral	moderate cost	competitive	0.6	0.5	acceptable	0.64	0.59	0.55	0.7	crowded field	Under 240 words	benefit+comp+cost+evidence+narrative+accept+confidence
VMC-006	neuro	drug-F	migraine	CGRP	similar efficacy	clean safety	RWE early	high cost	US mixed	0.65	0.52	borderline	0.61	0.6	0.53	0.69	fragile value	Under 240 words	benefit+comp+cost+evidence+narrative+accept+confidence

What this dataset tests

Whether a system can construct a coherent payer-facing value manifold.
It integrates clinical benefit, comparators, cost, and evidence strength.

Required outputs

clinical_benefit_axis
comparator_advantage_score
cost_effectiveness_position
evidence_strength_index
narrative_alignment_score
payer_acceptance_baseline
confidence_score

Use case

Optimize Phase III trial design.
Forecast reimbursement viability.
Strengthen payer-facing value narratives.

Downloads last month: 15

Number of rows:

Total file size:

7.27 kB